瑞芬太尼在老年患者快速序贯诱导中的有效性和安全性研究:一项三臂平行双盲随机对照试验

2020-06-04 罂粟花 罂粟花

老年患者快速序贯诱导(RSI),使用瑞芬太尼(0.5-1.0μg/kg)可预防心动过速和高血压的发生。

背景与目的

快速序贯诱导(RSI)被推荐用于误吸风险的患者,但会引起一系列血流动力学并发症:如心动过速等。本试验旨在评估老年患者RSI期间瑞芬太尼对下列情况发生风险的影响:心动过速、高血压和低血压。

方  法

在这项三臂平行双盲多中心对照研究中,三个医疗中心可进行RSI的老年患者(65 - 90岁)被随机分配到三组,使用依托咪酯(0.3 mg/kg)诱导麻醉,然后在15秒内使用安慰剂,或使用低剂量(0.5μg/kg)或高剂量(1.0μg/kg)瑞芬太尼,然后使用琥珀胆碱1.0 mg/kg。在插管前和插管后分别记录心率(HR)和平均动脉压(MAP)。

结  果

本试验最终共纳入80例患者,两组之间的基线水平HR和MAP无统计学差异。对于主要疗效指标心率和平均动脉压,对照组在诱导和插管之间的心率绝对值变化大于瑞芬太尼0.5μg/kg组和瑞芬太尼1.0μg/kg组。而对照组MAP的增加大于瑞芬太尼组(P< 0.0001)。对照组高血压发生次数是瑞芬太尼低剂量(0.5μg/kg)组和高剂量(1.0μg/kg)组的两倍(分别为60%、30%、28%;P=0.032),但对照组无低血压发作,瑞芬太尼低剂量(0.5μg/kg)组和高剂量(1.0μg/kg)组分别为11%和24%(P=0.016)。

结  论

老年患者快速序贯诱导(RSI),使用瑞芬太尼(0.5-1.0μg/kg)可预防心动过速和高血压的发生。

原始文献摘要

Ashokkumar Jayaraj, Hemavathi Balachander, Suresh K. Kuppusamy;Efficacy and Safety of Remifentanil in a Rapid Sequence Induction in elderly patients: a three-arm parallel double blind randomised controlled trial [J].Anaesth Crit Care Pain Med;

Background:

Rapid sequence induction (RSI) is recommended in patients at risk of aspiration, but induced hemodynamic adverse events, including tachycardia. In elderly patients, this trial aimed to assess the impact of the addition of remifentanil during RSI on the occurrence of: tachycardia(primary outcome), hypertension (due to intubation) nor hypotension (remifentanil). 

Methods:

In this three-arm parallel, double blind, multicentre controlled study, elderly patients (65 to 90 yearsold) hospitalised in three centres and requiring RSI were randomly allocated to three groups, where anaesthesia was induced with etomidate (0.3 mg/kg) followed within 15 seconds by either placebo, or low (0.5 μg/kg), or high (1.0 μg/kg) doses of Remifentanil, followed by succinylcholine 1.0 mg/kg.Heart rate (HR) and mean arterial pressure (MAP) were recorded before induction and after intubation. 

Results:

In total, eighty patients were randomised and analysed. Baseline HR and MAP were similar between groups. For primary endpoint, the absolute change in HR between induction and intubation was greater in the control group (15 bpm; 95% CI [8-21]) than that in the remifentanil 0.5 μg/kg group (4 bpm; 95% CI [-1-+8]; p = 0.005) and the remifentanil 1.0μg/kg group (-3 bpm; 95% CI [-9-+3]; p < 0.0001). The increase in MAP was greater in the placebo group than in both remifentanil groups (p < 0.0001). Twice as many hypertension episodes were recorded in the placebo group compared to the remifentanil 0.5 μg/kg and 1.0μg/kg groups (60%, 30%, and 28% patients respectively; p = 0.032), but no placebo patients experienced hypotension episodes versus 11% and 24% in the remifentanil 0.5 μg/kg and 1.0μg/kg groups respectively (p = 0.016). 

Conclusions:

Remifentanil (0.5-1.0 μg/kg) prevents the occurrence of tachycardia and hypertension in elderly patients requiring RSI.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2021-03-05 amyloid
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-06 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-06 xlxchina
  7. [GetPortalCommentsPageByObjectIdResponse(id=1987269, encodeId=1746198e269f8, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Feb 19 17:58:27 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775505, encodeId=81691e7550573, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Fri Mar 05 02:58:27 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296244, encodeId=a8c31296244fe, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384855, encodeId=797e138485550, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405269, encodeId=2c48140526902, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573088, encodeId=2ad815e3088d1, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Jun 06 05:58:27 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038929, encodeId=a3a010389294a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Thu Jun 04 17:58:27 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-04 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

相关资讯

Lancet:瑞芬太尼自控镇痛用于产前阵痛

研究认为瑞芬太尼病人自控镇痛对于分娩阵痛的控制效果优于哌替啶,有望成为分娩镇痛的新一线方法

瑞芬太尼在重症监护室镇痛镇静方案中的应用

提供有效的镇痛和充分的镇静是重症监护医学的普遍接受的目标。由于超短效的阿片类药物瑞芬太尼的快速、器官保护和代谢时间可预知等特性,使它对重症监护病房(ICU)中基于镇痛的镇静策略非常有用。

瑞芬太尼在早产儿脐血中的降解研究

Lars Welzing 等作者论证了瑞芬太尼在早产儿中代谢速率的问题,现对作者的文章进行总结。

重症医学:瑞芬太尼:重症监护病房镇痛镇静应用的综述

瑞芬太尼是一种芬太尼的4-苯胺哌啶衍生物,是一种超短效μ-阿片受体激动剂,可用于重症监护病房(ICU)中的机械通气患者,提供镇痛和镇静作用。 应用瑞芬太尼行镇痛为基础的镇静,对ICU中的机械通气患者来说,是一种有用的选择。其独特的特性(例如非器官依赖代谢、缺乏堆积、快速失效)使其不同于其他阿片类药物。在ICU机械通气患者中,瑞芬太尼至少与对比的阿片类药物如芬太尼、吗啡和舒芬太尼一样有效,可提

Anesthesia & Analgesia:右美托咪定与瑞芬太尼用于支气管内超声引导下支气管针吸活检术的监护性麻醉:随机对照试验

本研究假设,与瑞芬太尼相比,在非插管患者中右美托咪定用于支气管内超声引导下支气管针吸活检术(EBUS-TBNA)的监护性麻醉(MAC),较少引起主要呼吸系统不良事件发生(呼吸过缓、呼吸暂停和氧饱和度下降的发作次数),但围手术期满意度无差异。

Anaesthesia:瑞芬太尼与右美托咪定用于术中镇痛的比较:系统回顾与meta分析

术中瑞芬太尼的使用与术后镇痛需求及阿片类药物使用量增加有关。右美托咪定具有可取代瑞芬太尼用于术中全身麻醉的特点,但现有文献报道的结果之间相互矛盾。我们进行这项meta分析,旨在探讨是否使用包括右美托咪定在内的全身麻醉会比使用包括瑞芬太尼在内的全身麻醉所引起的术后疼痛更少。